trb_welcome.jpg

 

The mission of TRB Chemedica Group is to develop innovative and patented pharmaceutical products and medical devices in niche therapeutic areas: rheumatology, ophthalmology and neurology.


Video on Dry Eyeeye_pic.jpg

In recent years the nosology of Dry Eye has greatly changed. Professor Baudouin, MD, PhD from National Ophthalmologiy Hospital XV-XX, Vision Institute of Paris explains through this didactic video the complexity of the Dry Eye disease. Moving beyond the simple name of Dry Eye syndrome, we now consider the condition to be Dry Eye disease, insisting on the lack of tears, the lacrimal inflammation and hyperevaporation leading to self-sustaining loops of neurogenic and palpebral inflammations.

View the video


ostenil_plus.png

Mannitol-stabilised high dose HA for sustained effect

OSTENIL® PLUS is a unique combination of natural high dose HA (2%) + mannitol.
    
The formulation offers the possibility of reducing the number of intra-articular injections and increasing the intervals between injections. 

OSTENIL® PLUS reduces pain and improves function in osteoarthritis with very good tolerability.

Effective treatment with 1 to 3 injections of OSTENIL® PLUS

ostenil_plus.jpg
  
pdf OSTENIL® PLUS instructions for use
Distributors
trb_contact.gifContacts

News-Events
 
 
  • English